Introduction:
Millions of people worldwide suffer from a complicated neurological disease known as Alzheimer's disease. It was previously exclusively diagnosed based on clinical evaluations, with postmortem brain histology serving as confirmation. The discovery of reliable biomarkers for Alzheimer's disease has accelerated the creation of novel treatments and improved diagnostics. Alzheimer's disease-related alterations in blood flow to the brain and metabolic processes can be found and characterized using functional imaging techniques such as positron emission tomography (PET) and single photon emission computed tomography (SPECT). Early detection techniques that are sensitive and accurate may be available with radiotracer-based PET and SPECT.
What Is Alzheimer's Disease?
Affecting around fifty percent of all individuals over 85, Alzheimer's disease (AD) is the most prevalent source of dementia in older people. Alzheimer's disease (AD) is a progressive, permanent neurological disorder that gradually impairs thinking and memory abilities as well as the capacity to perform even the most basic daily tasks. There is no known cure for AD, even though treatment can help control its symptoms.
Lecanemab, a monoclonal antibody that focuses and aids in removing beta-amyloid, a protein that accumulates in the brains of people with Alzheimer's disease, was approved by the FDA (Food and Drug Administration) in 2023. Research indicated that the medication reduced cognitive and functional impairment by 27 percent.
In people with Alzheimer’s disease, there is abnormal deposition of two proteins, namely, tau and amyloid. Tau deposits lead to the formation of plaques, and amyloid deposition leads to the formation of neurofibrillary tangles. Neural function is impaired by abnormal accumulation of these proteins. Neuronal death results from progressive damage to individual neurons as well as the connections that connect them. The hippocampus, the brain's learning and memory region, is gradually affected by this process before it spreads to other brain regions.
According to scientists, these alterations in the brain start 10 to 20 years before the disease's symptoms manifest. Amyloid plaques and neurofibrillary tangles are invisible to standard brain imaging methods like computed tomography (CT) and magnetic resonance imaging (MRI) scans. However, with the help of molecular imaging, these characteristic features can be clearly seen.
What Is Molecular Imaging?
Molecular imaging is an aspect of imaging techniques in medicine that offers precise visualizations of molecular and cellular activity within the body. Molecular imaging techniques are secure, not painful, and noninvasive. Molecular imaging gives an understanding of anatomy and function, while other forms of diagnostic imaging, like computed tomography (CT), ultrasound, and X-rays, produce images of the anatomical structures.
Medical professionals can tailor patient care due to the distinctive perspectives that molecular imaging provides about the human body. Molecular imaging has the following diagnostic capabilities:
-
Offer details that cannot be acquired through conventional imaging methods or that would need additional procedures like surgery or a biopsy.
-
Assist in identifying the condition before the symptoms manifest.
-
Evaluate the abnormally functioning nerves or brain tissue in Alzheimer's disease and other neurological conditions.
-
Helps to determine the best course of treatment.
Which Molecular Imaging Technologies Are Employed for Alzheimer's Disease?
Currently, diagnosing AD is a difficult procedure that may involve a thorough patient history, neurological and physical examinations, laboratory testing, and a protracted process of ruling out other potential causes of mental impairment. Even though an autopsy performed after a patient passes away remains the sole means to make a conclusive diagnosis of AD, the Alzheimer's Association has released new diagnostic guidelines that highlight the significance of biomarkers like molecular neuroimaging. Molecular PET and SPECT imaging is a helpful diagnostic technique for AD and associated conditions.
What Is PET?
To perform positron emission tomography (PET), a radiotracer is injected into the bloodstream of the individual, along with an imaging device called a PET scanner. The PET radiotracer 18F-fluorodeoxyglucose (FDG), which is made from a simple sugar and a tiny quantity of radioactive fluorine, is widely used to assess dementia. FDG tracer is accumulated more by brain cells that are active. Additionally, AD can be distinguished from other types of dementia using FDG PET.
Amyloid plaques, which build up in AD, are specifically labeled by a radiotracer employed in amyloid PET. A positive amyloid PET is a strong indicator of AD in people under 60. In a patient exhibiting symptoms of dementia, a negative amyloid PET scan is highly suggestive of another type of dementia.
PET radiotracers accumulate in the body and release photons or tiny energy packets due to the organic decay of radiotracers, irrespective of the type of radiotracer used. These photons are detectable by the PET scanner, which then employs them to produce three-dimensional images that illustrate the radiotracer's distribution throughout the body.
What Is Single Photon Emission Computed Tomography?
In this method, a SPECT scanner and radiotracer are utilized. The radiotracer is injected into the bloodstream, and it gets deposited on the cells depending on the amount of blood flow they get. Since the function of the brain equates to the quantity of blood flow, the SPECT imaging shows high and low-activity regions in the brain, which may aid in the diagnosis of Alzheimer’s disease. The gamma photons produced by radiotracers are detectable by the SPECT scanner and produce a three-dimensional image of the body.
SPECT and PET scanners are frequently used in conjunction with CT to provide intricate pictures of the anatomy. Computed tomography imaging creates images with three dimensions by using sophisticated X-ray devices and, occasionally, contrast-enhancing substances.
How Are SPECT and PET Tests Carried Out?
-
First, the radiotracer is administered intravenously.
-
After this, the tracer is given time to spread across the body, which will require somewhere from 30 to 60 minutes.
-
After that, the individual is positioned inside the scanner, which uses detectors to provide a three-dimensional representation of the tracer concentration.
-
A trained radiology specialist, such as a radiologist or nuclear medicine doctor, analyzes and interprets scans and communicates the findings to the individual's doctor.
Conclusion
Molecular imaging, which makes use of PET scans, is one of the most active fields of study focused on developing novel methods for early Alzheimer's disease diagnosis. Molecular techniques have the potential to identify molecular indicators that Alzheimer's disease is progressing before the illness permanently damages cognitive abilities, memory, or logical thinking or modifies the structure or function of the brain. Additionally, molecular imaging might provide a fresh method for tracking the development of diseases and evaluating the efficacy of future drug therapies.
